RECURSION PHARMACEUTICALS, INC. (RXRX) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Win; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
32/58
2.8 / 5 stars
All 58 Win/Lose results and 62 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinRXRX / S&P 19.54% / 15.20% |
LoseRXRX / S&P -15.08% / 15.00% |
LoseRXRX / S&P -45.05% / 50.40% |
| 2026-Q10/3 |
LoseRXRX / S&P -24.94% / -4.33% |
LoseRXRX / S&P 11.07% / 11.30% |
LoseRXRX / S&P -35.91% / 27.70% |
| 2025-Q41/3 |
LoseRXRX / S&P -16.19% / 2.65% |
WinRXRX / S&P 26.92% / 9.00% |
LoseRXRX / S&P -15.29% / 13.40% |
| 2025-Q31/3 |
LoseRXRX / S&P -3.56% / 8.12% |
LoseRXRX / S&P -32.98% / 4.61% |
WinRXRX / S&P 18.71% / 13.45% |
| 2025-Q22/3 |
LoseRXRX / S&P -4.35% / 10.94% |
WinRXRX / S&P 30.14% / 4.83% |
WinRXRX / S&P 10.98% / 10.63% |
| 2025-Q12/3 |
LoseRXRX / S&P -21.75% / -4.27% |
WinRXRX / S&P 29.32% / 4.98% |
WinRXRX / S&P 11.73% / 10.57% |
| 2024-Q43/3 |
WinRXRX / S&P 2.58% / 2.41% |
WinRXRX / S&P 32.00% / 5.25% |
WinRXRX / S&P 8.28% / 6.15% |
| 2024-Q32/3 |
LoseRXRX / S&P -12.13% / 5.89% |
WinRXRX / S&P 37.64% / 5.89% |
WinRXRX / S&P 6.90% / 6.11% |
| 2024-Q21/3 |
LoseRXRX / S&P -24.77% / 4.28% |
LoseRXRX / S&P -0.70% / 5.38% |
WinRXRX / S&P 19.71% / 5.12% |
| 2024-Q11/3 |
LoseRXRX / S&P 1.12% / 10.56% |
LoseRXRX / S&P -0.88% / 5.71% |
WinRXRX / S&P 18.25% / 5.59% |
| 2023-Q43/3 |
WinRXRX / S&P 28.89% / 11.69% |
WinRXRX / S&P 11.88% / 6.81% |
WinRXRX / S&P 15.44% / 7.78% |
| 2023-Q33/3 |
WinRXRX / S&P 2.41% / -3.27% |
WinRXRX / S&P 65.02% / 7.52% |
WinRXRX / S&P -0.00% / -5.03% |
| 2023-Q23/3 |
WinRXRX / S&P 11.99% / 8.74% |
WinRXRX / S&P 176.57% / 9.50% |
WinRXRX / S&P -0.72% / -8.57% |
| 2023-Q12/3 |
LoseRXRX / S&P -13.49% / 7.50% |
WinRXRX / S&P 260.21% / 10.77% |
WinRXRX / S&P 4.58% / -15.69% |
| 2022-Q41/3 |
LoseRXRX / S&P -27.54% / 7.56% |
WinRXRX / S&P 291.46% / 11.88% |
LoseRXRX / S&P -41.13% / -17.99% |
| 2022-Q32/3 |
WinRXRX / S&P 30.71% / -4.88% |
WinRXRX / S&P 177.67% / 13.47% |
LoseRXRX / S&P -53.07% / -1.41% |
| 2022-Q22/3 |
WinRXRX / S&P 13.69% / -16.10% |
WinRXRX / S&P 104.76% / 13.71% |
LoseRXRX / S&P -64.62% / 11.04% |
| 2022-Q11/3 |
LoseRXRX / S&P -58.20% / -4.60% |
WinRXRX / S&P 100.32% / 15.97% |
LoseRXRX / S&P -70.69% / 42.23% |
| 2021-Q41/3 |
LoseRXRX / S&P -25.55% / 11.03% |
WinRXRX / S&P 156.89% / 15.00% |
LoseRXRX / S&P -42.11% / 96.40% |
| 2021-Q30/1 |
LoseRXRX / S&P -36.96% / 0.58% |
No dataRXRX / S&P / 10.77% |
No dataRXRX / S&P / 69.42% |
| 2021-Q20/0 |
No dataRXRX / S&P / 8.55% |
No dataRXRX / S&P / 6.58% |
No dataRXRX / S&P / 51.81% |
| 2021-Q10/0 |
No dataRXRX / S&P / 6.17% |
No dataRXRX / S&P / -1.06% |
No dataRXRX / S&P / 7.39% |
| 2020-Q40/0 |
No dataRXRX / S&P / 12.15% |
No dataRXRX / S&P / -3.72% |
No dataRXRX / S&P / -33.42% |
| 2020-Q30/0 |
No dataRXRX / S&P / 8.93% |
No dataRXRX / S&P / -2.04% |
No dataRXRX / S&P / -27.10% |
| 2020-Q20/0 |
No dataRXRX / S&P / 20.54% |
No dataRXRX / S&P / -0.46% |
No dataRXRX / S&P / -27.11% |
| 2020-Q10/0 |
No dataRXRX / S&P / -19.60% |
No dataRXRX / S&P / 3.47% |
No dataRXRX / S&P / -14.75% |
| 2019-Q40/0 |
No dataRXRX / S&P / 9.07% |
No dataRXRX / S&P / 5.36% |
No dataRXRX / S&P / 2.99% |
| 2019-Q30/0 |
No dataRXRX / S&P / 1.70% |
No dataRXRX / S&P / 5.02% |
No dataRXRX / S&P / 0.21% |
| 2019-Q20/0 |
No dataRXRX / S&P / 4.30% |
No dataRXRX / S&P / 6.64% |
No dataRXRX / S&P / 8.65% |
| 2019-Q10/0 |
No dataRXRX / S&P / 13.65% |
No dataRXRX / S&P / 8.12% |
No dataRXRX / S&P / 14.29% |
| 2018-Q40/0 |
No dataRXRX / S&P / -13.52% |
No dataRXRX / S&P / 9.05% |
No dataRXRX / S&P / 18.23% |
| 2018-Q30/0 |
No dataRXRX / S&P / 7.71% |
No dataRXRX / S&P / 10.21% |
No dataRXRX / S&P / 19.06% |
| 2018-Q20/0 |
No dataRXRX / S&P / 3.43% |
No dataRXRX / S&P / 9.03% |
No dataRXRX / S&P / 14.46% |
| 2018-Q10/0 |
No dataRXRX / S&P / -0.76% |
No dataRXRX / S&P / 7.68% |
No dataRXRX / S&P / 12.46% |
| 2017-Q40/0 |
No dataRXRX / S&P / 6.64% |
No dataRXRX / S&P / 7.03% |
No dataRXRX / S&P / 13.82% |
| 2017-Q30/0 |
No dataRXRX / S&P / 4.48% |
No dataRXRX / S&P / 5.68% |
No dataRXRX / S&P / 17.57% |
| 2017-Q20/0 |
No dataRXRX / S&P / 3.09% |
No dataRXRX / S&P / 4.83% |
No dataRXRX / S&P / 17.74% |
| 2017-Q10/0 |
No dataRXRX / S&P / 6.07% |
No dataRXRX / S&P / 3.67% |
No dataRXRX / S&P / 13.32% |
| 2016-Q40/0 |
No dataRXRX / S&P / 3.82% |
No dataRXRX / S&P / 2.09% |
No dataRXRX / S&P / 7.05% |
| 2016-Q30/0 |
No dataRXRX / S&P / 3.85% |
No dataRXRX / S&P / 0.20% |
No dataRXRX / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | RXRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -26.81% | 20.78% |
| Annualized return | -26.81% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | RXRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -86.12% | 83.14% |
| Annualized return | -32.63% | 12.86% |
10Y · 2021-04-16 to 2026-08-27
| Metric | RXRX total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -89.01% | 319.30% |
| Annualized return | -19.81% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |